KR100707895B1 - 푸린 유도체, 그의 제조 방법 및 이를 함유하는 제약 조성물 - Google Patents

푸린 유도체, 그의 제조 방법 및 이를 함유하는 제약 조성물 Download PDF

Info

Publication number
KR100707895B1
KR100707895B1 KR1020017014800A KR20017014800A KR100707895B1 KR 100707895 B1 KR100707895 B1 KR 100707895B1 KR 1020017014800 A KR1020017014800 A KR 1020017014800A KR 20017014800 A KR20017014800 A KR 20017014800A KR 100707895 B1 KR100707895 B1 KR 100707895B1
Authority
KR
South Korea
Prior art keywords
formula
radicals
radical
product
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017014800A
Other languages
English (en)
Korean (ko)
Other versions
KR20010113975A (ko
Inventor
장-루끄 해스렘
Original Assignee
아벤티스 파마 소시에떼아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아벤티스 파마 소시에떼아노님 filed Critical 아벤티스 파마 소시에떼아노님
Publication of KR20010113975A publication Critical patent/KR20010113975A/ko
Application granted granted Critical
Publication of KR100707895B1 publication Critical patent/KR100707895B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020017014800A 1999-05-21 2000-05-18 푸린 유도체, 그의 제조 방법 및 이를 함유하는 제약 조성물 Expired - Fee Related KR100707895B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9906456A FR2793794B1 (fr) 1999-05-21 1999-05-21 Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
FR99/06456 1999-05-21

Publications (2)

Publication Number Publication Date
KR20010113975A KR20010113975A (ko) 2001-12-28
KR100707895B1 true KR100707895B1 (ko) 2007-04-17

Family

ID=9545846

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017014800A Expired - Fee Related KR100707895B1 (ko) 1999-05-21 2000-05-18 푸린 유도체, 그의 제조 방법 및 이를 함유하는 제약 조성물

Country Status (33)

Country Link
US (2) US7122669B1 (https=)
EP (1) EP1183256B1 (https=)
JP (1) JP2003500407A (https=)
KR (1) KR100707895B1 (https=)
CN (1) CN1298719C (https=)
AP (1) AP1477A (https=)
AR (1) AR035317A1 (https=)
AT (1) ATE370951T1 (https=)
AU (1) AU4764500A (https=)
BR (1) BR0011282A (https=)
CA (1) CA2374714A1 (https=)
CZ (1) CZ20014163A3 (https=)
DE (1) DE60036102T2 (https=)
DK (1) DK1183256T3 (https=)
DZ (1) DZ3166A1 (https=)
EA (1) EA005072B1 (https=)
ES (1) ES2290033T3 (https=)
FR (1) FR2793794B1 (https=)
HU (1) HUP0201649A3 (https=)
IL (1) IL146441A0 (https=)
MA (1) MA26791A1 (https=)
MX (1) MXPA01011834A (https=)
NO (1) NO20015659L (https=)
NZ (1) NZ515556A (https=)
PL (1) PL352293A1 (https=)
PT (1) PT1183256E (https=)
SK (1) SK16722001A3 (https=)
TR (1) TR200103349T2 (https=)
TW (1) TWI284130B (https=)
UA (1) UA68441C2 (https=)
WO (1) WO2000071543A1 (https=)
YU (1) YU86601A (https=)
ZA (1) ZA200109602B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
AU3938802A (en) * 2000-10-31 2002-06-03 Aventis Pharma Inc Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
US6861524B2 (en) * 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
EP1578722A4 (en) * 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
WO2004035132A2 (en) * 2002-10-15 2004-04-29 Irm Llc Compositions and methods for inducing osteogenesis
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US7951592B2 (en) * 2003-11-10 2011-05-31 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
CA2563123A1 (en) * 2004-04-02 2005-10-20 Adenosine Therapeutics, Llc Selective antagonists of a2a adenosine receptors
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
CN114149432B (zh) * 2016-09-30 2024-07-05 斯坦福国际研究院 用于癌症治疗的双重clk/cdk1抑制剂
CZ308029B6 (cs) * 2017-03-20 2019-11-06 Univerzita PalackĂ©ho v Olomouci 2,6-Disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky
JP2026500305A (ja) 2022-12-16 2026-01-06 アストラゼネカ・アクチエボラーグ ２，６，９三置換プリン

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008858A1 (de) * 1990-03-20 1991-09-26 Hoechst Ag Substituierte purine, verfahren zu ihrer hertellung sowie ihre verwendung als antivirale mittel
EP0841810B1 (en) * 1991-12-05 2000-06-21 Texas Instruments Incorporated Method to improve a video signal
CA2084222C (en) * 1991-12-06 2004-04-06 David R. Borcherding Novel trans cyclopentanyl purine analogs useful as immunosuppressants
BR9611157A (pt) * 1995-11-01 1999-03-30 Novartis Ag Derivados de purina e processos para sua preparação
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
CA2297967A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
x 참증 없음 *

Also Published As

Publication number Publication date
SK16722001A3 (sk) 2003-01-09
CN1298719C (zh) 2007-02-07
PT1183256E (pt) 2007-11-13
JP2003500407A (ja) 2003-01-07
MXPA01011834A (es) 2002-04-17
EP1183256A1 (fr) 2002-03-06
KR20010113975A (ko) 2001-12-28
DE60036102D1 (de) 2007-10-04
IL146441A0 (en) 2002-07-25
CN1361780A (zh) 2002-07-31
FR2793794A1 (fr) 2000-11-24
ATE370951T1 (de) 2007-09-15
NZ515556A (en) 2003-08-29
CA2374714A1 (fr) 2000-11-30
DE60036102T2 (de) 2008-05-15
YU86601A (sh) 2005-07-19
US7122669B1 (en) 2006-10-17
EA005072B1 (ru) 2004-10-28
BR0011282A (pt) 2002-02-26
DZ3166A1 (fr) 2000-11-30
ES2290033T3 (es) 2008-02-16
NO20015659D0 (no) 2001-11-20
CZ20014163A3 (cs) 2002-10-16
AP1477A (en) 2005-10-19
US7208598B2 (en) 2007-04-24
US20050187228A1 (en) 2005-08-25
AU4764500A (en) 2000-12-12
AR035317A1 (es) 2004-05-12
EP1183256B1 (fr) 2007-08-22
HUP0201649A2 (en) 2002-08-28
WO2000071543A1 (fr) 2000-11-30
EA200101224A1 (ru) 2002-10-31
TR200103349T2 (tr) 2002-05-21
AP2001002355A0 (en) 2001-12-31
TWI284130B (en) 2007-07-21
MA26791A1 (fr) 2004-12-20
ZA200109602B (en) 2003-01-29
UA68441C2 (en) 2004-08-16
HUP0201649A3 (en) 2003-01-28
PL352293A1 (en) 2003-08-11
FR2793794B1 (fr) 2001-07-27
DK1183256T3 (da) 2007-12-03
NO20015659L (no) 2002-01-18

Similar Documents

Publication Publication Date Title
KR100707895B1 (ko) 푸린 유도체, 그의 제조 방법 및 이를 함유하는 제약 조성물
TWI851542B (zh) Ｓｈｐ２之八氫環戊烷并[c]吡咯別構抑制劑
CN107108671B (zh) 作为raf激酶抑制剂的化合物和组合物
JP7646632B2 (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
US11851428B2 (en) Activator of TREK (TWIK RElated K+channels) channels
TW201925182A (zh) 磺醯胺化合物及其用途
CA2816671A1 (en) Substituted 6-fluoro-1h-pyrazolo[4,3-b]pyridines and use thereof
RS63603B1 (sr) Sredstva za indukciju apoptoze
CA2973773C (en) 2-phenyl-3h-imidazo[4,5-b]pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ror1 activity
FR2820136A1 (fr) Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
TW200932727A (en) New acetyl coenzyme a carboxylase (ACC) inhibitors and uses in treatments of obesity and diabetes mellitus
JP2021519787A (ja) ６−アミノイソキノリンのモノ酸塩及びその使用
CN107660202A (zh) 水溶性前药
JP2007508364A (ja) Ｅｐ４受容体拮抗薬としてのフラン誘導体
JP2008525419A (ja) Ｈｉｖ−１逆転写酵素の非ヌクレオシド阻害剤
JP2017525727A (ja) プロテインキナーゼ阻害剤
AU2017382217A1 (en) Diaryl purine derivatives with improved bioavailability
CA3178647A1 (en) Substituted tricyclic amides, analogues thereof, and methods using same
FR2877667A1 (fr) Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
TW201536750A (zh) ３，５－二胺基吡唑激酶抑制劑之醫藥上可接受鹽
CN105153163A (zh) 2,9-二取代嘌呤-6-氨基异羟肟酸类组蛋白去乙酰化酶抑制剂及制备方法和应用
TWI920639B (zh) Shp2之八氫環戊烷并[c]吡咯別構抑制劑
AU2006202270A1 (en) Purine derivatives, preparation method and pharmaceutical compositions containing same
EA047339B1 (ru) Замещенные арилметилмочевины и гетероарилметилмочевины, их аналоги и способы их применения
WO2025216810A1 (en) Phenylalanine-based lat1 inhibitors and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100410

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100410

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000